Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00115570 · ClinicalTrials.gov registry record · Phase 3
Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and Adolescents
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 572
- Enrollment target
NCT00115570 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 572 participants.
The verdict
NCT00115570, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 572 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if insulin glulisine (Apidra) is as safe and effective a rapid acting insulin as insulin lispro (Humalog) in children and adolescents with type 1 diabetes mellitus.
Interventions
- DRUG insulin glargine
- DRUG Insulin glulisine
- DRUG insulin lispro
- DRUG NPH insulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 572 participants |
| Start Date | 2005-04 |
| Est. Completion | 2006-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00115570
The ClinicalTrials.gov registry entry for NCT00115570 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 572 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which insulin glargine is the first listed.
NCT00115570 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00115570 about?
NCT00115570 is a clinical study titled "Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and Adolescents". The purpose of this study is to determine if insulin glulisine (Apidra) is as safe and effective a rapid acting insulin as insulin lispro (Humalog) in children and adolescents with type 1 diabetes mellitus.
What is the current status of trial NCT00115570?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 572 participants. The study started on 2005-04. Estimated completion is 2006-11.
What interventions are being tested in trial NCT00115570?
The interventions under investigation include: insulin glargine (DRUG), Insulin glulisine (DRUG), insulin lispro (DRUG), NPH insulin (DRUG).
Who is sponsoring clinical trial NCT00115570?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.